plerixafor has been researched along with Prostatic Neoplasms in 10 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 10 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Zhao, ZF; Zhou, X; Zhu, WB | 1 |
Chen, FH; Chiang, CS; Fu, SY; Hong, JH; Wang, CC; Yang, YC | 1 |
Fujita, K; Hatano, K; Kaneda, Y; Murakami, K; Nagahara, A; Nakai, Y; Nakayama, M; Nimura, K; Nonomura, N; Tsuchiya, M; Uemura, M; Yamaguchi, S | 1 |
Biordi, L; Di Cesare, E; Festuccia, C; Gravina, GL; Jannini, EA; Mancini, A; Mattei, C; Muzi, P; Pompili, S; Ricevuto, E; Ventura, L | 1 |
Cher, ML; Chinni, SR; Conley-LaComb, MK; Heath, EI; Kim, S; Li, Y; Semaan, L; Singareddy, R | 1 |
Asara, JM; Avigan, DE; Balk, SP; Cantley, LC; Clohessy, JG; Csizmadia, E; Elemento, O; Gehring, MP; Helenius, K; Karp, JM; Kelly, K; Landon-Brace, N; Levantini, E; Montaser, L; Morgan, TM; Novak, J; Olson, BM; Pandolfi, PP; Patnaik, A; Pyzer, AR; Rosenblatt, JM; Signoretti, S; Solanki, A; Swanson, KD; Thornley, TB; Timmons, JJ; Wang, LC; Wang, Y; Ye, H | 1 |
Banie, L; Li, LC; Lin, CS; Lin, G; Lue, TF; Ning, H; Wang, G; Yang, R | 1 |
Bouchez, LC; Cho, CY; Dubrovska, A; Elliott, J; Kularatne, SA; Reddy, VA; Salamone, RJ; Schepotin, IB; Schultz, PG; Stakhovsky, AE; Telegeev, GD; Trussell, C; Wang, Y; Watson, J; Yan, F | 1 |
Ananias, HJ; de Jong, IJ; De Vries, EG; Domanska, UM; Huls, G; Kliphuis, NM; Kruizinga, RC; Nagengast, WB; Oude Munnink, TH; Timmer-Bosscha, H; Walenkamp, AM | 1 |
La Montagna, G; Mognetti, B; Pagliaro, P; Penna, C; Perrelli, MG | 1 |
10 other study(ies) available for plerixafor and Prostatic Neoplasms
Article | Year |
---|---|
AMD3100 inhibits epithelial-mesenchymal transition, cell invasion, and metastasis in the liver and the lung through blocking the SDF-1α/CXCR4 signaling pathway in prostate cancer.
Topics: Animals; Benzylamines; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Shape; Cell Survival; Chemokine CXCL12; Cyclams; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds; Liver Neoplasms; Lung Neoplasms; Male; Mice, Nude; Neoplasm Invasiveness; Neoplasm Proteins; Phosphorylation; Prostatic Neoplasms; Receptors, CXCR4; RNA, Messenger; Signal Transduction | 2019 |
Combination of vessel-targeting agents and fractionated radiation therapy: the role of the SDF-1/CXCR4 pathway.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzimidazoles; Benzylamines; Bone Marrow Cells; Chemokine CXCL12; Combined Modality Therapy; Cyclams; Dose Fractionation, Radiation; ErbB Receptors; Gefitinib; Green Fluorescent Proteins; Heterocyclic Compounds; Luminescent Agents; Male; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Pericytes; Prostatic Neoplasms; Quinazolines; Receptors, CXCR4; Tumor Microenvironment | 2013 |
Residual prostate cancer cells after docetaxel therapy increase the tumorigenic potential via constitutive signaling of CXCR4, ERK1/2 and c-Myc.
Topics: Animals; Antineoplastic Agents; Benzylamines; Carcinogenesis; Cell Line, Tumor; Cyclams; Disease Models, Animal; Docetaxel; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds; Humans; Male; MAP Kinase Signaling System; Mice, Nude; Mice, SCID; Neoplasm, Residual; Prostatic Neoplasms; Proto-Oncogene Proteins c-myc; Receptors, CXCR4; Signal Transduction; Taxoids | 2013 |
CXCR4 pharmacogical inhibition reduces bone and soft tissue metastatic burden by affecting tumor growth and tumorigenic potential in prostate cancer preclinical models.
Topics: Animals; Antineoplastic Agents; Antiviral Agents; Benzylamines; Blotting, Western; Bone Neoplasms; Cell Adhesion; Cell Movement; Chemokine CXCL12; Coculture Techniques; Cyclams; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Heterocyclic Compounds; Heterografts; Humans; Immunohistochemistry; Lymph Nodes; Lymphatic Metastasis; Male; Mice; Mice, Nude; Peptides; Prostatic Neoplasms; Receptors, CXCR4; Tomography, X-Ray Computed; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A | 2015 |
Pharmacological targeting of CXCL12/CXCR4 signaling in prostate cancer bone metastasis.
Topics: Animals; Benzylamines; Bone Neoplasms; Cell Line, Tumor; Chemokine CXCL12; Cyclams; Disease Models, Animal; ErbB Receptors; GTP-Binding Protein alpha Subunits, Gi-Go; Heterocyclic Compounds; Humans; Male; Membrane Microdomains; Mice; Phosphorylation; Prostatic Neoplasms; Receptor, ErbB-2; Receptors, CXCR4; Signal Transduction; src-Family Kinases; Xenograft Model Antitumor Assays | 2016 |
Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity.
Topics: Anilides; Animals; Benzylamines; Cell Line, Tumor; Cell Proliferation; Chemokine CXCL12; Cyclams; Heterocyclic Compounds; HMGB1 Protein; Humans; Immunity, Innate; Male; Mice; Neutrophils; Prostatic Neoplasms; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Pyridines; Tumor Microenvironment; Tumor Suppressor Protein p53 | 2017 |
Effects of transplantation of adipose tissue-derived stem cells on prostate tumor.
Topics: Adipose Tissue; Animals; Benzylamines; Cell Movement; Chemokine CXCL12; Cyclams; Fibroblast Growth Factor 2; Heterocyclic Compounds; Male; Mice; Mice, Nude; Microscopy, Fluorescence; Neovascularization, Pathologic; Prostatic Neoplasms; Random Allocation; Receptors, CXCR4; Stem Cell Transplantation; Vascular Endothelial Growth Factor A | 2010 |
CXCR4 expression in prostate cancer progenitor cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Cell Adhesion; Cell Proliferation; Chemokine CXCL12; Cyclams; Docetaxel; Heterocyclic Compounds; Humans; Male; Mice; Neoplasm Metastasis; Neoplastic Stem Cells; Prostatic Neoplasms; Receptors, CXCR4; Taxoids | 2012 |
CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzylamines; Bone Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Chemokine CXCL12; Cyclams; Docetaxel; Heterocyclic Compounds; Humans; Male; Mice; Prostatic Neoplasms; Random Allocation; Receptors, CXCR4; Taxoids; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2012 |
Bone marrow mesenchymal stem cells increase motility of prostate cancer cells via production of stromal cell-derived factor-1α.
Topics: Animals; Anti-HIV Agents; Benzylamines; Blotting, Western; Bone Marrow; Cell Movement; Cell Proliferation; Chemokine CXCL12; Culture Media, Conditioned; Cyclams; Heterocyclic Compounds; Humans; Male; Mesenchymal Stem Cells; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Rats; Tumor Cells, Cultured | 2013 |